With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros will look to fund ongoing clinical work via a listing that builds on this month’s series C round

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal disorders company filed a prospectus late Monday seeking up to $86.3 million via a NASDAQ listing.

The filing by Keros

Read the full 540 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE